GGHC
KLRS

Gilder Gagnon Howe & Co’s Kalaris Therapeutics KLRS Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-575
Closed -$509K – 411
2020
Q4 		$509K Sell
575
-26
-4% -$20K ﹤0.01% 285
2020
Q3 		$380K Buy
+601
New +$410K ﹤0.01% 287

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Gilder Gagnon Howe & Co's KLRS Position: Q1 2021 in Review

Gilder Gagnon Howe & Co sold out of Kalaris Therapeutics (KLRS) in Q1 2021, closing a stake of 575 shares — an estimated $509K sold.

Gilder Gagnon Howe & Co first reported a position in KLRS in Q3 2020 and held it in 2 quarters. The position peaked at $509K in Q4 2020. 75 funds tracked by Wall St. Rank hold KLRS as of Q1 2021.

  • Gilder Gagnon Howe & Co reported no remaining Kalaris Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 575 Kalaris Therapeutics shares in Q1 2021, an estimated $509K.
  • Gilder Gagnon Howe & Co first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Kalaris Therapeutics position peaked at $509K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2021, filed 17 May 2021.